Jefferies Group LLC reaffirmed their buy rating on shares of Accuray Incorporated (NASDAQ:ARAY) in a research note issued to investors on Wednesday morning. They currently have a $7.00 target price on the medical equipment provider’s stock.
A number of other research analysts have also weighed in on ARAY. BTIG Research reissued a hold rating on shares of Accuray in a research note on Sunday, April 30th. Zacks Investment Research lowered shares of Accuray from a buy rating to a hold rating in a research note on Tuesday, May 2nd. Finally, BidaskClub lowered shares of Accuray from a hold rating to a sell rating in a research note on Thursday, July 27th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. Accuray currently has a consensus rating of Hold and an average target price of $7.04.
Shares of Accuray (NASDAQ:ARAY) opened at 4.00 on Wednesday. The company’s market capitalization is $332.00 million. Accuray has a one year low of $3.85 and a one year high of $6.39. The stock has a 50 day moving average price of $4.47 and a 200 day moving average price of $4.69.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/08/13/accuray-incorporated-aray-stock-rating-reaffirmed-by-jefferies-group-llc.html.
Several hedge funds have recently made changes to their positions in ARAY. State Street Corp increased its stake in shares of Accuray by 8.0% in the fourth quarter. State Street Corp now owns 1,672,081 shares of the medical equipment provider’s stock worth $7,702,000 after buying an additional 124,566 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Accuray by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 672,494 shares of the medical equipment provider’s stock worth $3,093,000 after buying an additional 25,075 shares in the last quarter. Norges Bank purchased a new stake in shares of Accuray during the fourth quarter worth about $9,179,000. Teachers Advisors LLC increased its stake in shares of Accuray by 1.1% in the fourth quarter. Teachers Advisors LLC now owns 123,098 shares of the medical equipment provider’s stock worth $566,000 after buying an additional 1,314 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Accuray during the first quarter worth about $141,000. Institutional investors and hedge funds own 84.64% of the company’s stock.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.